180915-94-0

Basic information

• Product Name: 1-{2-[4-(6-METHOXY-3,4-DIHYDRO-1-NAFTYL)FENOXY]ETHYL}PYRROLIDINE
• Synonyms: 1-{2-[4-(6-METHOXY-3,4-DIHYDRO-1-NAFTYL)FENOXY]ETHYL}PYRROLIDINE
• CAS NO: 180915-94-0
• Molecular Formula: C₂₃H₂₇NO₂
• Molecular Weight: 349.46598
• Mol File: 180915-94-0.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 503.069°C at 760 mmHg
• Flash Point: 166.353°C
• Appearance: /
• Density: 1.12g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.589
• CAS DataBase Reference: 1-{2-[4-(6-METHOXY-3,4-DIHYDRO-1-NAFTYL)FENOXY]ETHYL}PYRROLIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-{2-[4-(6-METHOXY-3,4-DIHYDRO-1-NAFTYL)FENOXY]ETHYL}PYRROLIDINE(180915-94-0)
• EPA Substance Registry System: 1-{2-[4-(6-METHOXY-3,4-DIHYDRO-1-NAFTYL)FENOXY]ETHYL}PYRROLIDINE(180915-94-0)

Safety Data

• Hazardous Substances Data: 180915-94-0(Hazardous Substances Data)

Usage

InChI:InChI=1/C23H27NO2/c1-25-21-11-12-23-19(17-21)5-4-6-22(23)18-7-9-20(10-8-18)26-16-15-24-13-2-3-14-24/h6-12,17H,2-5,13-16H2,1H3

Upstream product

• 1081-73-8 1-[2-(4-bromophenoxy)ethyl]pyrrolidine 
• 60-29-7 diethyl ether 
• 1078-19-9 6-methoxy-3,4-dihydro-1(2H)-naphthalenone 

Downstream Products

• 180915-95-1 1-{2-[4-(2-Bromo-6-methoxy-3,4-dihydronaphthalen-1-yl)phenoxy] ethyl}pyrrolidine 

Relevant articles and documents

A new process for the synthesis of nafoxidene as a key intermediate of lasofoxifene

Abstract A novel brief process for the synthesis of nafoxidene has been developed. The epoxidation of 6-methoxy-1-{4-[2-(pyrrolin-1-yl)ethoxy)]phenyl}-3,4-dihydronaphthalene by m-CPBA directly gave the ketone 6-methoxy-1-[4-(2-(pyrrolidin-1-yl)ethoxy)phenyl]-3,4-dihydronaphthalen-2(1H)-one, which was subject to phenyl magnesium bromide/cerium chloride and subsequently treated with an acid to yield nafoxidene. In addition, the preparation of the starting naphthalene was also optimized by replacing the aromatic lithium at low temperature with its Grignard reagent at refluxing THF. This mild process, without the use of toxic or noble metals, was more cost-efficient and easily worked up.

Pharmaceutical composition and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and an estrogen agonist/antagonist

The present invention relates to pharmaceutical compositions and methods of treatment comprising administering to a patient in need thereof a combination of a 2-alkylidene-19-nor-vitamin D derivative and an estrogen agonistlantagonist or a pharmaceuticall

Estrogen agonists/antagonists

Compounds of formula A inhibit bone resorption and bone turnover, prevent bone loss, preserve bone strength and decrease serum cholesterol without causing prostate hypertrophy in male mammals: and E and B are selected from CH and N. R4 is H, OH, F or Cl.